Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. Mounjaro revenue jumped 91% to $9.9 billion, while Zepbound climbed 46% to $4.9 billion, and together they anchored a quarter where US sales rose 33% to $14.4 billion, and international sales rose 80% to $8.6 billion. Management responded by lifting full-year revenue guidance to a range of $85 billion to $87 billion, up from $82 billion to $85 billion previously. Bear Case: The Cost Of Growing This FastThe same quarter that produced 48% revenue growth also showed what that growth is costing. The forward price-to-earnings ratio of 32.89 puts Lilly well above the broader market, pricing in continued double-digit growth from here.